Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanofi has initiated a Phase 2 clinical study titled A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM). The study aims to assess the efficacy of this combination therapy in adult patients with RRMM who have undergone 1 to 3 prior treatments, focusing on the overall response rate.
The intervention being tested involves a combination of drugs: Isatuximab administered subcutaneously via an on-body delivery system, Carfilzomib, and Dexamethasone. This combination is designed to treat RRMM by leveraging the synergistic effects of these medications.
This is an interventional study with a single-group assignment, meaning all participants receive the same treatment. It is open-label, so both researchers and participants know the treatment being administered. The primary goal is treatment efficacy.
The study began on March 17, 2025, with primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 7, 2025, indicating the study is actively recruiting participants.
For investors, the progress of this study could influence Sanofi’s stock performance, as successful results may enhance the company’s position in the oncology market, particularly in treating multiple myeloma. Competitors in the oncology space may also be affected as new treatment options emerge.
The study is ongoing, with further details available on the ClinicalTrials portal.